• Search History (Register)
  • MeSH Browser
  • [Clear]
    • English

Welcome to the international HTA database


Showing [17098 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2026     National Institute for Health and Care Excellence (NICE) Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer. NICE technology appraisal guidance 1127
2026     National Institute for Health and Care Excellence (NICE) Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer. NICE technology appraisal guidance 1130
2026     National Institute for Health and Care Excellence (NICE) Obinutuzumab with mycophenolate mofetil for treating lupus nephritis. NICE technology appraisal guidance 1131
2026     National Institute for Health and Care Excellence (NICE) Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy. NICE technology appraisal guidance 1129
2026     National Institute for Health and Care Excellence (NICE) Ruxolitinib for treating moderate to severe chronic graft versus host disease after an allogeneic stem cell transplant in people 28 days to 17 years (terminated appraisal). NICE technology appraisal guidance 1132
2026     National Institute for Health and Care Excellence (NICE) Dupilumab for treating severe chronic rhinosinusitis with nasal polyps. NICE technology appraisal guidance 1134
2026     National Institute for Health and Care Excellence (NICE) Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma. NICE technology appraisal guidance 1133
2026     National Institute for Health and Care Excellence (NICE) Baloxavir marboxil for treating and preventing influenza in children 1 to 11 years (terminated appraisal). NICE technology appraisal guidance 1135
2026     National Institute for Health and Care Excellence (NICE) Canagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal). NICE technology appraisal guidance 1137
2026     National Institute for Health and Care Excellence (NICE) Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. NICE technology appraisal guidance 1136
2026     Health Information and Quality Authority (HIQA) Protocol for the health technology assessment of the introduction of population-based screening for familial hypercholesterolaemia in children
2026     Health Information and Quality Authority (HIQA) The management of acute asthma attack in adults
2026     Health Information and Quality Authority (HIQA) Paediatric early warning system in emergency settings
2026     NIHR Health Services and Delivery Research programme Ethnic differences in injury mortality rates among adult emergency healthcare service users in high-income countries: a scoping review
2026     NIHR Health Technology Assessment programme Mapping components of behavioural weight management interventions using electronic survey and component selection by expert consensus: the BE:COME Study
2026     NIHR Health Services and Delivery Research programme Utilisation of the support workforce in diagnostic imaging: a mixed-methods investigation
2026     NIHR Health Technology Assessment programme Intravenous lidocaine for gastrointestinal recovery after colorectal surgery: the ALLEGRO placebo-controlled randomised trial and cost-effectiveness analysis
2026     NIHR Health Technology Assessment programme Magnetic resonance enterography to predict disabling disease in newly diagnosed Crohn’s disease: the METRIC-EF multivariable prediction model, multicentre diagnostic inception cohort study
2026     NIHR Health Technology Assessment programme Enzyme replacement therapy compared with best supportive care for the treatment of Pompe Disease: a systematic review and network meta-analysis
2026     NIHR Health Services and Delivery Research programme Asymptomatic testing compared with standard care of the care home staff in shaping care home COVID-19 testing policy: the VIVALDI-CT pragmatic cluster RCT (VIVALDI-CT)
2026     HTA South [Clinical benefit of photon-counting computed tomorgraphy - a systematic review and assessment of medical, economical, ethical and organisational aspects]
2026     NIHR Health Technology Assessment programme Laparoscopic hysterectomy versus open abdominal hysterectomy for women with a benign gynaecological condition: the LAVA RCT
2026     NIHR Health Services and Delivery Research programme Developing research resources and minimum data set for care homes’ adoption and use (DACHA)
2026     NIHR Health Technology Assessment programme The clinical and cost-effectiveness of improving sleep via carer delivered strategies in people with dementia: the DREAMS START parallel multi-centre RCT
2026     NIHR Health Technology Assessment programme The clinical and cost-effectiveness of paravertebral blockade versus thoracic epidural blockade in reducing chronic post-thoracotomy pain: TOPIC2 RCT synopsis
2026     NIHR Health Technology Assessment programme Conservative versus liberal oxygenation targets in critically ill children: the Oxy-PICU RCT
2026     NIHR Health Technology Assessment programme Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a randomised placebo-controlled trial
2026     NIHR Health Technology Assessment programme Outcome after Selective early treatment for Closure of patent ductus ARteriosus in preterm babies, a multicentre, masked, randomised placebo-controlled parallel group trial (Baby-OSCAR trial)
2026     NIHR Health Technology Assessment programme Artificial Intelligence technologies for assessing skin lesions for referral on the urgent suspected cancer pathway to detect benign lesions and reduce secondary care specialist appointments: early value assessment
2026     NIHR Health Technology Assessment programme Gabapentin as an adjunct to multimodal pain regimens in surgical patients: the GAP placebo-controlled RCT and economic evaluation
2026     NIHR Health Technology Assessment programme Establishing the safety of waterbirth for mothers and their babies: the POOL cohort study with nested qualitative component
2026     NIHR Health Technology Assessment programme A pragmatic, multicentre, placebo-controlled, 3-arm, double-blinded, randomised controlled trial, incorporating an internal pilot, to determine the role of bronchodilators in preventing exacerbations of bronchiectasis
2026     NIHR Health Technology Assessment programme Roux-en-Y gastric bypass, adjustable gastric banding or sleeve gastrectomy for severe obesity: the By-Band-Sleeve randomised controlled trial
2026     NIHR Health Technology Assessment programme Digitally enabled therapy for chronic tic disorders and Tourette Syndrome: a systematic review and economic evaluation
2026     NIHR Health Technology Assessment programme The impact and cost-effectiveness of scaling up HCV treatment for achieving elimination among people who inject drugs in England: a synopsis including evidence synthesis and economic modelling
2026     National Institute for Health and Care Excellence (NICE) Balloon cryoablation for Barrett's oesophagus. NICE HealthTech guidance 767
2026     National Institute for Health and Care Excellence (NICE) Digital self-help for eating disorders: early value assessment. NICE HealthTech guidance 768
2026     National Institute for Health and Care Excellence (NICE) Digital technologies for managing mild to moderate symptoms of hip or knee osteoarthritis: early value assessment. NICE HealthTech guidance 766
2026     National Institute for Health and Care Excellence (NICE) Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia. NICE technology appraisal guidance 1119
2026     National Institute for Health and Care Excellence (NICE) Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal). NICE technology appraisal guidance 1118
2026     National Institute for Health and Care Excellence (NICE) Avelumab with axitinib for untreated advanced renal cell carcinoma. NICE technology appraisal guidance 1120
2026     National Institute for Health and Care Excellence (NICE) Acoramidis for treating transthyretin amyloidosis with cardiomyopathy. NICE technology appraisal guidance 1121
2026     National Institute for Health and Care Excellence (NICE) Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 1122
2026     National Institute for Health and Care Excellence (NICE) Depemokimab for treating chronic rhinosinusitis with nasal polyps in adults (terminated appraisal). NICE technology appraisal guidance 1123
2026     National Institute for Health and Care Excellence (NICE) Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma (terminated appraisal). NICE technology appraisal guidance 1125
2026     National Institute for Health and Care Excellence (NICE) Concizumab for treating haemophilia A or B in people 12 years and over with factor inhibitors (terminated appraisal). NICE technology appraisal guidance 1124
2026     National Institute for Health and Care Excellence (NICE) Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy. NICE technology appraisal guidance 1126
2026     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of medical management versus surgery for deep infiltrating endometriosis: synopsis from the DIAMOND RCT
2026     NIHR Health Technology Assessment programme Addition of early vocational advice to usual primary care on sickness absence in employed adults: exploratory findings from the discontinued WAVE Randomised Controlled Trial
2026     NIHR Health Services and Delivery Research programme Referral pathways into the NHS Digital Weight Management Programme for musculoskeletal and perioperative patients: rapid process evaluation
2026     NIHR Health Technology Assessment programme Methods and mechanisms for measuring and monitoring outcomes from newborn bloodspot screening: a scoping review
2026     NIHR Health Services and Delivery Research programme Models of perinatal care for women using drugs and their infants: synopsis of The Stepping Stones Study
2026     NIHR Health Technology Assessment programme Home-based extended rehabilitation for older people with frailty (HERO): a multicentre randomised controlled trial with health economic analysis and process evaluation
2026     NIHR Health Technology Assessment programme Reducing self-harm in adolescents: the RISA-IPD comprehensive synopsis
2026     NIHR Health Technology Assessment programme Timing of birth to improve outcomes in chronic or gestational hypertension: the WILL RCT
2026     NIHR Health Technology Assessment programme Treatments for renal cell carcinoma: NICE Pilot Treatment Pathways Appraisal
2026     NIHR Health Services and Delivery Research programme A randomised feasibility trial of an intervention involving mental health support workers as link workers to improve dental visiting in people with severe mental illness: The Mouth Matters in Mental Health Study
2026     NIHR Health Technology Assessment programme Relative and bedside nurse assessment of comfort and communication during propofol, dexmedetomidine, or clonidine-based sedation: pre-planned analysis within the A2B RCT
2026     Health Information and Quality Authority (HIQA) A health technology assessment (HTA) of cochlear implants for adults with single-sided deafness
2026     Health Information and Quality Authority (HIQA) Rapid health technology assessment on the use of vesicostomy buttons in children
2026     Health Information and Quality Authority (HIQA) Protocol for a systematic review on the association between alcohol consumption and mental health outcomes
2026     Scottish Health Technologies Group (SHTG) Virtual wards
2026     Health Information and Quality Authority (HIQA) Scalable Training and Knowledge Exchange on guideline development for patients, public, and healthcare professionals (The STAKEholder Project)
2026     Health Technology Wales (HTW) Capsule sponge devices to detect Barrett’s oesophagus and early-stage oesophageal cancer
2026     Health Information and Quality Authority (HIQA) Protocol for modelling the risk of alcohol-attributable mortality and hospital admission in Ireland
2026     Health Information and Quality Authority (HIQA) Health technology assessment of extending BowelScreen to those aged 50 to 54 years
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Neurosurgical robot for electrode implantation, brain biopsies and spinal surgery]
2026     Belgian Health Care Knowledge Centre (KCE) Assessment of a mobile application in the rehabilitation of patients undergoing primary knee or hip arthroplasty (Study 2020-01)
2026     Belgian Health Care Knowledge Centre (KCE) Economic evaluation based on ‘PRECISe’, a randomised clinical trial funded by the KCE Trials programme (Study 2024-92)
2026     Health Information and Quality Authority (HIQA) Health technology assessment of RSV immunisation
2026     Swiss Federal Office of Public Health (FOPH) Valerian extracts for sleep disorders, anxiety or restlessness
2026     Swiss Federal Office of Public Health (FOPH) Ginkgo biloba in patients with decreasing mental performance, peripheral arterial occlusive disease, vertigo or tinnitus
2026     Swiss Federal Office of Public Health (FOPH) Thermoablation for benign thyroid nodules
2026     Swiss Federal Office of Public Health (FOPH) Injection therapies with corticosteroids for chronic tendinopathy or enthesopathy
2026     Swiss Federal Office of Public Health (FOPH) Superficial/deep heat in physiotherapy for musculoskeletal conditions
2025     Austrian Institute for Health Technology Assessment (AIHTA) Long-term effectiveness and safety of enzyme replacement therapy in mucopolysaccharidosis type I, II, IVA and Pompe disease: a systematic review
2025     Austrian Institute for Health Technology Assessment (AIHTA) Dorocubicel + unexpanded CD34– cells (Zemcelpro®) for the treatment of haematological malignancies in adults
2025     WorkSafeBC Effect of ropinirole on patients with myoclonic dystonia: 2025 update
2025     WorkSafeBC Osteoarthritis of the knee and foot orthoses
2025     WorkSafeBC Cervical disc herniation and cervical spine degeneration
2025     WorkSafeBC COVID-19 vaccine and systemic lupus erythematosus (SLE)
2025     WorkSafeBC Use of supplements to treat patients diagnosed with sciatica
2025     WorkSafeBC Firefighting and Hodgkins lymphoma
2025     WorkSafeBC Hypertension and firefighting
2025     WorkSafeBC Platelet rich plasma (PRP) in treating post-fracture ankle pain
2025     WorkSafeBC External trigeminal nerve stimulation (e-TNS) in treating and preventing migraine headaches
2025     Agency for Care Effectiveness (ACE) Toripalimab for first-line systemic treatment of recurrent or metastatic nasopharyngeal carcinoma
2025     Agency for Care Effectiveness (ACE) Momelotinib for treating myelofibrosis in patients with moderate to severe anaemia
2025     Agency for Care Effectiveness (ACE) Datopotamab deruxtecan for previously treated unresectable or metastatic HR-positive, HER2-negative breast cancer
2025     Agency for Care Effectiveness (ACE) Onasemnogene abeparvovec for treating spinal muscular atrophy
2025     Agency for Care Effectiveness (ACE) Sotorasib for previously treated KRAS G12C-mutated locally advanced or metastatic non-small-cell lung cancer
2025     Agency for Care Effectiveness (ACE) Sucroferric oxyhydroxide for treating hyperphosphataemia in patients with end-stage renal disease on dialysis
2025     Agency for Care Effectiveness (ACE) Talazoparib in combination with enzalutamide for treating HRR gene-mutated metastatic castration-resistant prostate cancer
2025     Agency for Care Effectiveness (ACE) Durvalumab with or without olaparib for treating primary advanced or recurrent endometrial cancer
2025     Agency for Care Effectiveness (ACE) Tislelizumab for treating locally advanced or metastatic non-squamous non-small-cell lung cancer without EGFR or ALK genomic tumour aberrations
2025     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of technologies for the assessment of attention deficit hyperactivity disorder: a systematic review and economic model
2025     Scottish Health Technologies Group (SHTG) Digital prevention programmes for people at risk of developing type 2 diabetes
2025     Scottish Health Technologies Group (SHTG) Electrocardiogram (ECG) patch monitors for the detection of cardiac rhythm abnormalities
2025     Scottish Health Technologies Group (SHTG) Home blood pressure monitoring for people with suspected or confirmed hypertension
2025     Agency for Care Effectiveness (ACE) Hydrogel rectal spacers for rectum protection during radiation therapy for prostate cancer